Multiple sclerosis at menopause: Potential neuroprotective effects of estrogen

Maturitas

Volumn 80, Issue 2, 2015, Pages 133-139

  Christianson, Mindy S ^a   Mensah, Virginia A ^b   Shen, Wen ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WOMEN AND INFANTS HOSPITAL   (United States)

Author keywords

Estradiol; Estrogen; Hormone therapy; Menopause; Multiple sclerosis; Neuroprotection

Indexed keywords

CYTOKINE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GAMMA INTERFERON; GESTAGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12; INTERLEUKIN 2; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; PROGESTERONE DERIVATIVE; PROTEIN BAX; PROTEIN BCL 2; TUMOR NECROSIS FACTOR ALPHA; NEUROPROTECTIVE AGENT;

ALZHEIMER DISEASE; AUTOIMMUNE DISEASE; CELL MATURATION; CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; CYTOKINE PRODUCTION; DEMYELINATION; DENDRITIC CELL; DISEASE ASSOCIATION; DISEASE EXACERBATION; ENCEPHALITIS; ESTROGEN THERAPY; HUMAN; MENOPAUSE; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; PATHOPHYSIOLOGY; PUERPERIUM; REVIEW; DISEASE COURSE; ENERGY METABOLISM; FEMALE; METABOLISM; NERVE CELL;

CYTOKINES; DISEASE PROGRESSION; ENERGY METABOLISM; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MENOPAUSE; MULTIPLE SCLEROSIS; NEURONS; NEUROPROTECTIVE AGENTS;

EID: 84922621172     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2014.11.013     Document Type: Review

References (96)

1. Gomez FP, Steelman AJ, Young CR, Welsh CJ. Hormone and immune systeminteractions in demyelinating disease. Horm Behav 2013;63: 315-21.
2. Whitacre CC. Sex differences in autoimmune disease. Nat Immunol2001;2: 777-80.
3. Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T.Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in MultipleSclerosis Group. N Engl J Med 1998;339: 285-91.
4. Spence RD, Voskuhl RR. Neuroprotective effects of estrogens and andro-gens in CNS inflammation and neurodegeneration. Front Neuroendocrinol2012;33: 105-15.
5. Gold SM, Voskuhl RR. Estrogen and testosterone therapies in multiple sclerosis.Prog Brain Res 2009;175: 239-51.
6. Kipp M, Amor S, Krauth R, Beyer C. Multiple sclerosis: Neuroprotective allianceof estrogen-progesterone and gender. Front Neuroendocrinol 2012;33: 1-16.
7. Lassmann H. Multiple sclerosis pathology: Evolution of pathogenetic concepts.Brain Pathol 2005;15: 217-22.
8. van der Valk P, De Groot CJ. Staging of multiple sclerosis (MS) lesions: Pathologyof the time frame of MS. Neuropathol Appl Neurobiol 2000;26: 2-10.
9. Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: Pathologyof the newly forming lesion. Ann Neurol 2004;55: 458-68.
10. Racke MK, Lovett-Racke AE, Karandikar NJ. The mechanism of action ofglatiramer acetate treatment in multiple sclerosis. Neurology 2010;74(Suppl1): S25-30.
11. Rudick RA, Goelz SE. Beta-interferon for multiple sclerosis. Exp Cell Res2011;317: 1301-11.
12. Abramsky O. Pregnancy and multiple sclerosis. Ann Neurol 1994;36(Suppl.): S38-41.
13. Chruzander C, Johansson S, Gottberg K, Einarsson U, Fredrikson S, HolmqvistLW, et al. A 10-year follow-up of a population-based study of people withmultiple sclerosis in Stockholm, Sweden: Changes in disability and thevalue of different factors in predicting disability and mortality. J Neurol Sci2013;332: 121-7.
14. Vukusic S, Hutchinson M, Hours M, Moreau T, Cortinovis-Tourniaire P, AdeleineP, et al. Pregnancy and multiple sclerosis (the PRIMS study): Clinical predictorsof post-partum relapse. Brain 2004;127: 1353-60.
15. Smith R, Studd JW. A pilot study of the effect upon multiple sclerosis of themenopause, hormone replacement therapy and the menstrual cycle. J R SocMed 1992;85: 612-3.
16. Miller H. The management of multiple sclerosis. Med World 1955;83: 426-8.
17. Vukusic S, Ionescu I, El-Etr M, Schumacher M, Baulieu EE, Cornu C, et al. ThePrevention of Post-Partum Relapses with Progestin and Estradiol in MultipleSclerosis (POPART'MUS) trial: Rationale, objectives and state of advancement.J Neurol Sci 2009;286: 114-8.
18. Ghezzi A, Zaffaroni M. Female-specific issues in multiple sclerosis. Expert RevNeurother 2008;8: 969-77.
19. McCombe PA, Greer JM. Female reproductive issues in multiple sclerosis. MultScler 2013;19: 392-402.
20. Al-Shammri S, Rawoot P, Azizieh F, AbuQoora A, Hanna M, Saminathan TR, et al.Th1/Th2 cytokine patterns and clinical profiles during and after pregnancy inwomen with multiple sclerosis. J Neurol Sci 2004;222: 21-7.
21. Soldan SS, Alvarez Retuerto AI, Sicotte NL, Voskuhl RR. Immune modulationin multiple sclerosis patients treated with the pregnancy hormone estriol. JImmunol 2003;171: 6267-74.
22. Boulware MI, Kent BA, Frick KM. The impact of age-related ovarian hor-mone loss on cognitive and neural function. Curr Top Behav Neurosci2012;10: 165-84.
23. Rocca WA, Grossardt BR, Shuster LT. Oophorectomy, menopause, estrogentreatment, and cognitive aging: Clinical evidence for a window of opportunity.Brain Res 2011;1379: 188-98.
24. Holmqvist P, Hammar M, Landtblom AM, Brynhildsen J. Age at onset of multiplesclerosis is correlated to use of combined oral contraceptives and childbirthbefore diagnosis. Fertil Steril 2010;94: 2835-7.
25. Hernan MA, Hohol MJ, Olek MJ, Spiegelman D, Ascherio A. Oral contraceptivesand the incidence of multiple sclerosis. Neurology 2000;55: 848-54.
26. Holmqvist P, Wallberg M, Hammar M, Landtblom AM, Brynhildsen J. Symptomsof multiple sclerosis in women in relation to sex steroid exposure. Maturitas2006;54: 149-53.
27. Sicotte NL, Liva SM, Klutch R, Pfeiffer P, Bouvier S, Odesa S, et al. Treat-ment of multiple sclerosis with the pregnancy hormone estriol. Ann Neurol2002;52: 421-8.
28. El-Etr M, Ghoumari A, Sitruk-Ware R, Schumacher M. Hormonal influ-ences in multiple sclerosis: New therapeutic benefits for steroids. Maturitas2011;68: 47-51.
29. Bove R, Chitnis T, Houtchens M. Menopause in multiple sclerosis: Therapeuticconsiderations. J Neurol 2014;261: 1257-68.
30. Brinton RD. The healthy cell bias of estrogen action: Mitochondrial bioenerget-ics and neurological implications. Trends Neurosci 2008;31: 529-37.
31. Kajta M, Beyer C. Cellular strategies of estrogen-mediated neuroprotectionduring brain development. Endocrine 2003;21: 3-9.
32. Dhandapani KM, Brann DW. Role of astrocytes in estrogen-mediated neuro-protection. Exp Gerontol 2007;42: 70-5.
33. Ghisletti S, Meda C, Maggi A, Vegeto E. 17beta-estradiol inhibits inflammatorygene expression by controlling NF-kappaB intracellular localization. Mol CellBiol 2005;25: 2957-68.
34. Acs P, Kipp M, Norkute A, Johann S, Clarner T, Braun A, et al. 17Beta-estradiol andprogesterone prevent cuprizone provoked demyelination of corpus callosumin male mice. Glia 2009;57: 807-14.
35. Nilsen J, Chen S, Irwin RW, Iwamoto S, Brinton RD. Estrogen protects neuronalcells from amyloid beta-induced apoptosis via regulation of mitochondrial pro-teins and function. BMC Neurosci 2006;7: 74.
36. Struble RG, Nathan BP, Cady C, Cheng X, McAsey M. Estradiol regulation ofastroglia and apolipoprotein E: An important role in neuronal regeneration.Exp Gerontol 2007;42: 54-63.
37. Arnold S, Beyer C. Neuroprotection by estrogen in the brain: The mitochondrialcompartment as presumed therapeutic target. J Neurochem 2009;110: 1-11.
38. Alkayed NJ, Goto S, Sugo N, Joh HD, Klaus J, Crain BJ, et al. Estrogen and Bcl-2: Gene induction and effect of transgene in experimental stroke. J Neurosci2001;21: 7543-50.
39. Du S, Sandoval F, Trinh P, Umeda E, Voskuhl R. Estrogen receptor-beta ligandtreatment modulates dendritic cells in the target organ during autoimmunedemyelinating disease. Eur J Immunol 2011;41: 140-50.
40. Pike CJ. Estrogen modulates neuronal Bcl-xL expression and beta-amyloid-induced apoptosis: Relevance to Alzheimer's disease. J Neurochem1999;72: 1552-63.
41. Nilsen J. Estradiol and neurodegenerative oxidative stress. Front Neuroen-docrinol 2008;29: 463-75.
42. Scott E, Zhang QG, Wang R, Vadlamudi R, Brann D. Estrogen neuroprotectionand the critical period hypothesis. Front Neuroendocrinol 2012;33: 85-104.
43. Zhang QG, Han D, Wang RM, Dong Y, Yang F, Vadlamudi RK, et al. C termi-nus of Hsc70-interacting protein (CHIP)-mediated degradation of hippocampalestrogen receptor-alpha and the critical period hypothesis of estrogen neuro-protection. Proc Natl Acad Sci USA 2011;108: E617-24.
44. Croxford AL, Kurschus FC, Waisman A. Mouse models for multiple sclero-sis: Historical facts and future implications. Biochim Biophys Acta 2011;1812: 177-83.
45. Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy ofmultiple sclerosis via animal models: 70 years of merits and culprits in exper-imental autoimmune encephalomyelitis research. Brain 2006;129: 1953-71.
46. Herz J, Zipp F, Siffrin V. Neurodegeneration in autoimmune CNS inflammation.Exp Neurol 2010;225: 9-17.
47. Mix E, Meyer-Rienecker H, Hartung HP, Zettl UK. Animal models of multiplesclerosis-potentials and limitations. Prog Neurobiol 2010;92: 386-404.
48. Slavin A, Kelly-Modis L, Labadia M, Ryan K, Brown ML. Pathogenic mech-anisms and experimental models of multiple sclerosis. Autoimmunity2010;43: 504-13.
49. Beeson PB. Age and sex associations of 40 autoimmune diseases. Am J Med1994;96: 457-62.
50. Fairweather D, Frisancho-Kiss S, Rose NR. Sex differences in autoimmune dis-ease from a pathological perspective. Am J Pathol 2008;173: 600-9.
51. Lockshin MD. Sex differences in autoimmune disease. Lupus 2006;15: 753-6.
52. Martocchia A, Stefanelli M, Cola S, Falaschi P. Sex steroids in autoimmunediseases. Curr Top Med Chem 2011;11: 1668-83.
53. McCombe PA, Greer JM, Mackay IR. Sexual dimorphism in autoimmune disease.Curr Mol Med 2009;9: 1058-79.
54. Noonan CW, Kathman SJ, White MC. Prevalence estimates for MS in theUnited States and evidence of an increasing trend for women. Neurology2002;58: 136-8.
55. Jansson L, Olsson T, Holmdahl R. Estrogen induces a potent suppression ofexperimental autoimmune encephalomyelitis and collagen-induced arthritisin mice. J Neuroimmunol 1994;53: 203-7.
56. McClain MA, Gatson NN, Powell ND, Papenfuss TL, Gienapp IE, Song F, et al.Pregnancy suppresses experimental autoimmune encephalomyelitis throughimmunoregulatory cytokine production. J Immunol 2007;179: 8146-52.
57. Voskuhl RR, Peterson RS, Song B, Ao Y, Morales LB, Tiwari-Woodruff S, et al.Reactive astrocytes form scar-like perivascular barriers to leukocytes duringadaptive immune inflammation of the CNS. J Neurosci 2009;29: 11511-22.
58. Arnold AP, Chen X. What does the four core genotypes mouse model tell usabout sex differences in the brain and other tissues. Front Neuroendocrinol2009;30: 1-9.
59. Brenner T, Evron S, Abramsky O. Effect of experimental autoimmuneencephalomyelitis on pregnancy: Studies in rabbits and rats. Isr J Med Sci1991;27: 181-5.
60. Evron S, Brenner T, Abramsky O. Suppressive effect of pregnancy on the devel-opment of experimental allergic encephalomyelitis in rabbits. Am J ReprodImmunol 1984;5: 109-13.
61. Gatson NN, Williams JL, Powell ND, McClain MA, Hennon TR, Robbins PD, et al. Induction of pregnancy during established EAE halts progression of CNSautoimmune injury via pregnancy-specific serum factors. J Neuroimmunol2011;230: 105-13.
62. Korn-Lubetzki I, Kahana E, Cooper G, Abramsky O. Activity of multiple sclerosisduring pregnancy and puerperium. Ann Neurol 1984;16: 229-31.
63. Matejuk A, Adlard K, Zamora A, Silverman M, Vandenbark AA, Offner H. 17Beta-estradiol inhibits cytokine, chemokine, and chemokine receptor mRNAexpression in the central nervous system of female mice with experimentalautoimmune encephalomyelitis. J Neurosci Res 2001;65: 529-42.
64. Matejuk A, Dwyer J, Hopke C, Vandenbark AA, Offner H. 17Beta-estradiol treat-ment profoundly down-regulates gene expression in spinal cord tissue in miceprotected from experimental autoimmune encephalomyelitis. Arch ImmunolTher Exp (Warsz) 2003;51: 185-93.
65. Subramanian S, Matejuk A, Zamora A, Vandenbark AA, Offner H. Oralfeeding with ethinyl estradiol suppresses and treats experimental autoim-mune encephalomyelitis in SJL mice and inhibits the recruitment ofinflammatory cells into the central nervous system. J Immunol 2003;170: 1548-55.
66. Bodhankar S, Wang C, Vandenbark AA, Offner H. Estrogen-induced protec-tion against experimental autoimmune encephalomyelitis is abrogated in theabsence of B cells. Eur J Immunol 2011;41: 1165-75.
67. Bebo Jr BF, Fyfe-Johnson A, Adlard K, Beam AG, Vandenbark AA, OffnerH. Low-dose estrogen therapy ameliorates experimental autoimmuneencephalomyelitis in two different inbred mouse strains. J Immunol2001;166: 2080-9.
68. Offner H. Neuroimmunoprotective effects of estrogen and derivatives in exper-imental autoimmune encephalomyelitis: Therapeutic implications for multiplesclerosis. J Neurosci Res 2004;78: 603-24.
69. Almolda B, Gonzalez B, Castellano B. Antigen presentation in EAE: Roleof microglia, macrophages and dendritic cells. Front Biosci (Landmark Ed)2011;16: 1157-71.
70. Liu HY, Buenafe AC, Matejuk A, Ito A, Zamora A, Dwyer J, et al. Estrogeninhibition of EAE involves effects on dendritic cell function. J Neurosci Res2002;70: 238-48.
71. Offner H, Vandenbark AA. Congruent effects of estrogen and T-cell recep-tor peptide therapy on regulatory T cells in EAE and MS. Int Rev Immunol2005;24: 447-77.
72. Gold SM, Sasidhar MV, Morales LB, Du S, Sicotte NL, Tiwari-Woodruff SK, et al.Estrogen treatment decreases matrix metalloproteinase (MMP)-9 in autoim-mune demyelinating disease through estrogen receptor alpha (ERalpha). LabInvest 2009;89: 1076-83.
73. Subramanian S, Yates M, Vandenbark AA, Offner H. Oestrogen-mediated pro-tection of experimental autoimmune encephalomyelitis in the absence ofFoxp3+ regulatory T cells implicates compensatory pathways including reg-ulatory B cells. Immunology 2011;132: 340-7.
74. Kim S, Liva SM, Dalal MA, Verity MA, Voskuhl RR. Estriol ameliorates autoim-mune demyelinating disease: Implications for multiple sclerosis. Neurology1999;52: 1230-8.
75. Palaszynski KM, Liu H, Loo KK, Voskuhl RR. Estriol treatment ameliorates dis-ease in males with experimental autoimmune encephalomyelitis: Implicationsfor multiple sclerosis. J Neuroimmunol 2004;149: 84-9.
76. Papenfuss TL, Powell ND, McClain MA, Bedarf A, Singh A, Gienapp IE, et al. Estriolgenerates tolerogenic dendritic cells in vivo that protect against autoimmunity.J Immunol 2011;186: 3346-55.
77. Lelu K, Delpy L, Robert V, Foulon E, Laffont S, Pelletier L, et al. Endogenousestrogens, through estrogen receptor alpha, constrain autoimmune inflamma-tion in female mice by limiting CD4+ T-cell homing into the CNS. Eur J Immunol2010;40: 3489-98.
78. Lelu K, Laffont S, Delpy L, Paulet PE, Perinat T, Tschanz SA, et al.Estrogen receptor alpha signaling in T lymphocytes is required for estradiol-mediated inhibition of Th1 and Th17 cell differentiation and protectionagainst experimental autoimmune encephalomyelitis. J Immunol 2011;187: 2386-93.
79. Polanczyk M, Zamora A, Subramanian S, Matejuk A, Hess DL, Blankenhorn EP, et al. The protective effect of 17beta-estradiol on experimental autoimmuneencephalomyelitis is mediated through estrogen receptor-alpha. Am J Pathol2003;163: 1599-605.
80. Crawford DK, Mangiardi M, Song B, Patel R, Du S, Sofroniew MV, et al. Oestro-gen receptor beta ligand: A novel treatment to enhance endogenous functionalremyelination. Brain 2010;133: 2999-3016.
81. Elloso MM, Phiel K, Henderson RA, Harris HA, Adelman SJ. Suppression of exper-imental autoimmune encephalomyelitis using estrogen receptor-selectiveligands. J Endocrinol 2005;185: 243-52.
82. Morales LB, Loo KK, Liu HB, Peterson C, Tiwari-Woodruff S, Voskuhl RR. Treat-ment with an estrogen receptor alpha ligand is neuroprotective in experimentalautoimmune encephalomyelitis. J Neurosci 2006;26: 6823-33.
83. Tiwari-Woodruff S, Morales LB, Lee R, Voskuhl RR. Differential neuroprotectiveand antiinflammatory effects of estrogen receptor (ER)alpha and ERbeta ligandtreatment. Proc Natl Acad Sci USA 2007;104: 14813-8.
84. Garcia-Ovejero D, Veiga S, Garcia-Segura LM, Doncarlos LL. Glial expressionof estrogen and androgen receptors after rat brain injury. J Comp Neurol2002;450: 256-71.
85. Garidou L, Laffont S, Douin-Echinard V, Coureau C, Krust A, Chambon P, et al.Estrogen receptor alpha signaling in inflammatory leukocytes is dispens-able for 17beta-estradiol-mediated inhibition of experimental autoimmuneencephalomyelitis. J Immunol 2004;173: 2435-42.
86. Mitra SW, Hoskin E, Yudkovitz J, Pear L, Wilkinson HA, Hayashi S, et al.Immunolocalization of estrogen receptor beta in the mouse brain: Comparisonwith estrogen receptor alpha. Endocrinology 2003;144: 2055-67.
87. Perez SE, Chen EY, Mufson EJ. Distribution of estrogen receptor alpha and betaimmunoreactive profiles in the postnatal rat brain. Brain Res Dev Brain Res2003;145: 117-39.
88. Vegeto E, Bonincontro C, Pollio G, Sala A, Viappiani S, Nardi F, et al. Estrogenprevents the lipopolysaccharide-induced inflammatory response in microglia.J Neurosci 2001;21: 1809-18.
89. Spence RD, Hamby ME, Umeda E, Itoh N, Du S, Wisdom AJ, et al. Neuroprotectionmediated through estrogen receptor-alpha in astrocytes. Proc Natl Acad Sci USA2011;108: 8867-72.
90. Arvanitis DN, Wang H, Bagshaw RD, Callahan JW, Boggs JM. Membrane-associated estrogen receptor and caveolin-1 are present in central nervoussystem myelin and oligodendrocyte plasma membranes. J Neurosci Res2004;75: 603-13.
91. Hirahara Y, Matsuda K, Gao W, Arvanitis DN, Kawata M, Boggs JM. The localiza-tion and non-genomic function of the membrane-associated estrogen receptorin oligodendrocytes. Glia 2009;57: 153-65.
92. Platania P, Laureanti F, Bellomo M, Giuffrida R, Giuffrida-Stella AM, CataniaMV, et al. Differential expression of estrogen receptors alpha and beta in thespinal cord during postnatal development: Localization in glial cells. Neuroen-docrinology 2003;77: 334-40.
93. Takao T, Flint N, Lee L, Ying X, Merrill J, Chandross KJ. 17beta-estradiol pro-tects oligodendrocytes from cytotoxicity induced cell death. J Neurochem2004;89: 660-73.
94. Polanczyk M, Yellayi S, Zamora A, Subramanian S, Tovey M, VandenbarkAA, et al. Estrogen receptor-1 (Esr1) and -2 (Esr2) regulate the severity ofclinical experimental allergic encephalomyelitis in male mice. Am J Pathol2004;164: 1915-24.
95. Saijo K, Collier JG, Li AC, Katzenellenbogen JA, Glass CK. An ADIOL-ERbeta-CtBPtransrepression pathway negatively regulates microglia-mediated inflamma-tion. Cell 2011;145: 584-95.
96. Chesik D, De Keyser J. Progesterone and dexamethasone differentially regulatethe IGF-system in glial cells. Neurosci Lett 2010;468: 178-82.